However, a phase 2 trial of the JNK inhibitor CC-930 in idiopathic pulmonary fibrosis was halted due to acute liver toxicity, although reductions in markers of lung fibrosis were noted (van der Velden et al., 2016). The gene discussed is MAPK8; the disease is pulmonary fibrosis.